Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has received FDA acceptance for the resubmission of its NDA for STS101, a novel treatment for acute migraine. This milestone aligns with SNBL’s financial forecasts for the fiscal year ending March 2025, as the U.S. market for such treatments exceeds $1 billion.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.